Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpuraMatthieu Jestin, Paul Coppo, Y. Benhamou et al.|Blood|2018Cited by 163
Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic PurpuraMélanie Roriz, Paul Coppo, Mickaël Landais et al.|Medicine|2015Cited by 72
Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survivalRenaud Prével, Paul Coppo, Claire Roubaud‐Baudron et al.|Blood|2019Cited by 61
Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)Paul Coppo, Marie Scully, Xiaopu Zheng et al.|EClinicalMedicine|2025Cited by 41
Twice‐daily therapeutical plasma exchange‐based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French <scp>TMA</scp> Reference Center experienceMyriam Soucemarianadin, Paul Coppo, Y. Benhamou et al.|European Journal Of Haematology|2015Cited by 28